BDAZ - Thank you for your reply. At the AGM it was explained that the new revenue area for the companies that produced enzalutamide and abiratarone is somewhere past the mid point of the 2 dotted lines, 16 to 32 weeks. Since I don't know enough to question or argue one way or another I could only accept what I was told. 

I'm still unsure about wether the patients in the de Bono JS et al article were or were not responding at the time of being switched to enzalutamide. 

Given your explanation it is easier to understand why we haven't had an offer to be taken out yet.

tada